Allergy Therapeutics (AGY)

 

Latest News

Director Deals - Allergy Therapeutics PLC (AGY)

Peter Jensen, Chairman, bought 30,000 shares in the company on the 29th September 2016 at a price of 19.25p. The Director ...

Director/PDMR Shareholding

RNS Number: 2273L Allergy Therapeutics PLC 29 September 2016 29 September 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Board of Allergy Therapeutics was info...

Director Deals - Allergy Therapeutics PLC (AGY)

Nick Wykeman, Financial Director, bought 150,000 shares in the company on the 27th September 2016 at a price of 17.75p. T...

Director/PDMR Shareholding

RNS Number: 0114L Allergy Therapeutics PLC 28 September 2016 28 September 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Board of Allergy Therapeutics was infor...

All News

DateHeadlineSource
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
26-09-16Director/PDMR ShareholdingRNS
26-09-16Hardman Research: Performance drives market shareRNS
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics Preliminary ResultsRNS
21-09-16Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
21-09-16Allergy Therapeutics options exercised StockMarketWire
20-09-16Issue of equity in respect of exercise of optionsRNS
05-09-16Allergy Therapeutics schedules FY results StockMarketWire
05-09-16Notice of Preliminary ResultsRNS
31-08-16Allergy Therapeutics Plc to present at the Shares Investor Evening in London on 27th September 2016StockMarketWire
13-07-16Trading UpdateRNS
08-07-16Results of mite immunotherapy Acarovac PlusTRNS
27-06-16Findings from mEEC dose range finding study G204RNS
13-06-16Allergy Therapeutics' satellite symposium at EAACIStockMarketWire
13-06-16Allergy hosts Satellite Symposium at EAACIRNS
10-06-16Appointment of Finance DirectorRNS
18-05-16Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breedMotley Fool
09-05-16Allergy Therapeutics positive data from PQBirch204 studyStockMarketWire
09-05-16Positive Phase II DataRNS
21-04-16This list of shares keeps outperformingInteractive Investor
23-03-16Allergy Therapeutics options exercised StockMarketWire
23-03-16Issue of equity in respect of options exerciseRNS
17-03-16Allergy Therapeutics FD resigns StockMarketWire
17-03-16Board ChangeRNS
14-03-16Allergy Therapeutics grants options under LTIP StockMarketWire
11-03-16Grant of Options under Long Term Incentive PlanRNS
10-03-16Broker Forecast - Panmure Gordon issues a broker note on Allergy Therapeutics PLCStockMarketWire
08-03-16Interim Results for the six months ended 31/12/15RNS
24-02-16Hardman & Co Research Report: Development ProgressRNS
23-02-16Allergy Therapeutics schedules interim resultsStockMarketWire
23-02-16Notice of Interim ResultsRNS
18-02-16Allergy Therapeutics completes patient enrolmentStockMarketWire
18-02-16Patient enrolment completed in US Phase IIb studyRNS

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory